GRAIL has announced that two of its executives will be speaking at the BofA Securities 2020 Health Care Conference.
Hans Bishop, Chief Executive Officer; and Joshua Ofman, MD, MSHS, Chief Medical Officer and External Affairs, will provide an overview of the company at the virtual conference, which will take place Wednesday, May 13, 2020, at 5 p.m. ET.
GRAIL is coming off a very good year. In March, the company announced that validation data for its multi-cancer early detection test were published in Annals of Oncology. The data show that GRAIL’s technology can detect more than 50 cancer types across all stages, with a false positive rate of less than 1 percent, through a single blood draw. The test can also identify the tissue of origin—where the cancer is located in the body—with 93 percent accuracy.
In April, GRAIL presented new data evaluating the performance of its liquid biopsy in symptomatic participants with suspicion of cancer at the American Association for Cancer Research Virtual Annual Meeting. “We continue to make significant progress in the validation of our multi-cancer early detection blood test, and wanted to assess its potential to drive efficiencies in the diagnostic workup of patients who are showing symptoms,” GRAIL Co-founder, Chief Scientific Officer, and Head of R&D Alex Aravanis, MD, Ph.D said at the time.
On May 6, GRAIL announced that it had completed a $390 million Series D financing round. The funds will be used to support continued development and commercialization of its multi-cancer detection blood test.
A live and archived audio webcast of Bishop and Ofman’s talk will be available online.
Read the original press release here.